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Background: In recent decades, shared decision-making (SDM) models have been developed 
to increase patient involvement in treatment decisions. The purpose of this study was to examine 
the effect of a shared decision-making intervention (SDMI) for substance-dependent patients 
on patients’ and clinicians’ perceptions of therapeutic alliance.
Methods: Clinicians were randomly assigned to SDMI or usual procedures to reach a treatment 
agreement. SDMI is a structured, manualized, 5-session procedure to facilitate treatment 
agreement and consists of ﬁ ve standardized sessions.
Results: Patients’ perceptions of the therapeutic alliance were very favorable at start of treatment, 
and no differences were found between intervention groups. Clinicians’ scores on perceived 
helpfulness and on the overall therapeutic alliance were higher in the SDMI group than in the 
controls, after 8 weeks of treatment and at the end of treatment.
Conclusion: The present study has shown that a speciﬁ c intervention to enhance shared 
decision-making results in favorable changes in clinicians’ perceptions of the therapeutic 
alliance.
Keywords: therapeutic alliance, helping alliance, shared decision-making, addiction, 
substance-dependence
Introduction
Studies in the recent decades have demonstrated that the quality of the therapeutic 
relationship is a signiﬁ cant predictor of treatment adherence and outcome in addiction 
health care (Meier et al 2005). The collaborative aspects of the therapeutic relationship 
are generally described as therapeutic alliance (Hougaard 1994). Therapeutic alliance is 
not equal to therapeutic relationship, although the relationship may inﬂ uence alliance. 
It is formed in the complex interaction between the patient and the clinician (Baldwin 
et al 2007). Therapeutic alliance has been deﬁ ned in a number of ways but most 
deﬁ nitions identify therapeutic alliance as the mutual collaboration between clinician 
and patient, which includes emotional bonding, a sense of warmth and openness, and 
shared expectations of both tasks and goals of therapy (Connors et al 1997). Therapeutic 
alliance related terms are working alliance and helping alliance. Working alliance 
emphasizes patient’s ability to work purposively in the treatment situation (Greenson, 
1965). Helping alliance concerns patient’s experience of treatment or relationship with 
the clinician as helpful or potentially helpful (Luborsk 1976).
One aspect of this deﬁ nition is the patient-clinician agreement on tasks and goals. 
This aspect is strongly related to shared decision-making (SDM) (Fische 2006). 
In recent years, the patient-clinician relationship has become more of a partnership 
or a collaboration (Charles et al 1999). Clinicians now adopt more of a “we” rather 
than a “me” approach to treatment (Fuertes et al 2007). SDM is a new and important 
aspect in such collaboration. SDM is deﬁ ned as an approach in which clinician and 
patient go through all phases of the decision-making process together and in which they 
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share the preference for treatment and reach an agreement on 
treatment choice (Charles et al 1999). Legislation has been 
passed in several countries aimed at strengthening the inﬂ u-
ence of patients (Crawford et al 2003). In the Netherlands, 
patient involvement in decision-making about treatment has 
been formally prescribed in a speciﬁ c law (WGBO), and 
the principle of identifying patient’s view is increasingly 
presented in national guidelines for health care professionals 
(Van der Weijden et al 2007).
In the treatment of substance abuse there is, as in somatic 
care, increasing emphasis on patient autonomy and active 
involvement in decision-making (Robinson and Thomson 
2001). De Jong-Verhagen and De Jong (2001) recommended 
the use of a structured procedure to systematically list and 
rank patients’ goals and expectations, preferably at different 
times during treatment. This procedure leads to a dialogue 
between clinician and patient regarding treatment goals and 
expectations, resulting in a treatment agreement which may 
be adapted during treatment. Discussing with patients about 
choices, especially about the goal of treatment, is expected 
to lead to better treatment outcome (Sanchez-Craig 1990). 
This dialogue between patient and clinician is also expected 
to lead to improvement in the therapeutic alliance (Hamann 
et al 2006). In order to discuss structurally and frequently 
and evaluate a wide range of problem areas and treatment 
goals to reach a treatment agreement, SDM intervention 
was developed.
Numerous modern mental health interventions have 
supported patient-centered care, patient choice, and self-
directed care, but research on SDM in mental health care is 
just beginning (Adams and Drake 2006; Joosten et al 2008). 
To date, only a few studies have explored the effect of SDM 
on the therapeutic alliance. Results of these studies were con-
tradictory. Bieber et al (2006) found that a computer based 
information tool for ﬁ bromyalgia syndrome patients and 
SDM communication training for clinicians improved clini-
cian-patient relationship from both clinicians’ and patients’ 
perspectives. The effect of this SDM communication train-
ing was stronger for patients than for clinicians (Bieber et al 
2008). A SDM program for inpatients with schizophrenia 
appeared to have no effect on clinicians’ perception of the 
therapeutic relationship (Hamann et al 2006). There is exten-
sive literature on related issues, particularly on the therapeutic 
alliance, but mental health care literature speciﬁ cally dealing 
with SDM has just started (Fischer 2006).
We developed a SDM intervention (SDMI) for patients 
dependent on psychoactive substances in addiction health 
care programs. Patients and clinicians systematically and 
frequently discuss and evaluate a wide range of treatment 
goals. SDMI offers a structured and well-balanced 5-session 
intervention to reach and carry out joint treatment decisions. 
The aim of the present study was to examine the effect of a 
SDMI for substance-dependent patients on the therapeutic 
alliance. In this study we focused on the therapeutic alliance 
as an important aspect of the therapeutic relationship. The 
therapeutic alliance was examined from both patient and 
clinician perspectives. We hypothesized that patient’s and 
clinician’s perceived alliance would improve as a result of 
SDMI. We also hypothesized that patient’s and clinician’s 
perceived alliance will be more congruent when SDMI is 
carried out.
Methods
A randomized controlled trial (RCT) was conducted in three 
addiction treatment centers in the Netherlands. Patients were 
recruited from January 2005 to May 2006.
Study design
This study was conducted in clinical practice. Randomization 
took place at baseline at the level of clinicians and within each 
site to avoid carry-over effect. We randomized at the level of 
clinicians to minimize the effect of clinician characteristics 
on the outcome measure. Elvins and Green (2008) stated 
that research on therapeutic alliance should focus on RCTs 
to account for variability in clinician characteristics. Further-
more, this way of randomization was the most feasible and 
scientiﬁ cally justiﬁ able procedure. Randomization schedule 
was generated by computer, and allowed us to randomly 
allocate the clinicians into two conditions. Clinicians in the 
experimental condition were trained in the protocols of the 
SDM intervention method. The other condition consisted 
of reaching and evaluating a regular treatment agreement 
(non-structured) without SDMI. Neither study participants 
nor study staff were blinded to the intervention. Whether or 
not patients received SDMI depended on the clinician the 
patients were allocated to. Patients were allocated to one 
of the clinicians by availability at baseline. Therefore, this 
allocation can be considered as random because it was only 
based on accidental events like patients leaving treatment, 
clinicians’ duty, and vacation schedule.
Participants
Participants were recruited from three addiction treatment 
centers in the Netherlands. Participating patients were 
dependent on psychoactive substances and needed inpatient 
treatment programs. In this study, clinicians were nurses 
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or social workers who had most contact with the patients. 
The clinicians worked at the inpatient treatment unit. All 
participating centers had comparable 3-month inpatient 
treatment programs which included individual as well as 
group aspects. This inpatient treatment included aspects of 
cognitive behavioral therapy. All patients applying for help 
in one of these treatment programs during the study period 
were included in the study. No distinction was made regard-
ing type of substance used. Patients were excluded for the 
following reasons: being under the age of 18 years; insuf-
ﬁ cient knowledge of the Dutch language; severe psychiatric 
co-morbidity that would preclude to take part in the process of 
SDM and adherence to the protocol; and no informed consent 
to participate in the study. At follow-up evaluation, patients 
received a voucher of €20. The study was approved by the 
Dutch Ethical Assessment Committee for Experimental 
Investigations on People (No 4.108).
Measures
Baseline characteristics were measured by the European 
Addiction Severity Index (EuropASI) and Composite Inter-
national Diagnostic Interview – Substance Abuse Module 
(CIDI-SAM). EuropASI, is a clinical research interview 
designed to assess problem severity in six areas: physical 
health; employment; alcohol and/or drug use; legal; family/
social; and psychiatric (McLellan et al 1980). In this study 
the Dutch version of EuropASI was used which also contains 
gambling (Hendriks et al 1989; Hartgens et al 1994). Eight 
severity scores, with ranges 0 (no problem) to 9 (extremely 
serious problem), were derived from this interview.
Type and severity of substance dependence was assessed 
by using CIDI-SAM (Compton et al 1996). CIDI-Substance 
Abuse Module (SAM) is an expanded and more detailed 
version of the substance use sections of the Composite 
International Diagnostic Interview (CIDI).
Therapeutic alliance was measured by the Helping 
Alliance Questionnaire (HAQ). The HAQ is a self-report 
questionnaire that measures the strength of patient-clinician 
alliance (Alexander and Luborsky 1984; Luborsky et al 
1996). The Dutch version of the HAQ has 11 items which 
are rated on a 5-point likert scale (completely disagree, 
disagree, neither disagree nor agree, agree, completely agree) 
(De Weert-Van Oene et al 1999). A patient, as well as a 
clinician version, has been developed. This questionnaire 
measures helping alliance at an individual level (eg, “I feel 
the therapist understands me.”; “I understand the patient.”). 
This HAQ contains 2 scales: Cooperation (α = 0.88), a 
5-item scale reﬂ ecting the perception of the patient to work 
together with the therapist and vice versa; and Helpfulness 
(α = 0.76), a 5-item scale referring to the patient’s conﬁ -
dence in his own capacities in improving the situation and 
the clinician’s conﬁ dence in his/her capacities to improve 
the situation. The helpfulness scale also refers to clinician 
or treatment effectiveness. HAQ is easy to complete and 
interpret. Psychometric properties of the HAQ are satisfac-
tory (De Weert-Van Oene et al 1999).
The Goals of Treatment questionnaire was used in the 
experimental condition as part of the intervention. The Goals 
of Treatment questionnaire was partly based on the Camber-
well Assessment of Need (Phelan et al 1995; McCrone et al 
2000; Varo et al 2002) but also covered two additional areas: 
Gambling and Legal. Areas of problems were translated 
into “goals” of which the patient could tick whether s/he 
wanted to work on this deﬁ nitely, possibly or deﬁ nitely not. 
The clinician indicated per goal whether to his/ her opinion 
the patient had to work on it deﬁ nitely, possibly or deﬁ nitely 
not during treatment.
The procedure of completing the Goals of Treatment 
questionnaire was extended with a Q-sort ranking (Cronbach 
1990) to indicate importance and priority of each goal of this 
questionnaire. These were cards on which the 24 treatment 
goals were described. Patient and clinician had to arrange 
these cards in the same way as the goals of the questionnaire 
were arranged in (deﬁ nitely, possibly or deﬁ nitely not). After 
this, the piles deﬁ nitely and possibly were arranged in order 
of importance and priority. Patients and clinicians could 
discuss the differences between their indicated priority of 
each treatment goal by means of these Q-sort cards.
Intervention
SDMI contains 5 sessions. In the introduction session 
(session I), at the beginning of the treatment, the clinician 
introduces the procedure of SDMI to the patient. At the end 
of this session the patient is handed over the questionnaire 
and Q-sort cards. One week after the introduction session 
(session II), patient’s treatment goals and expectations are 
explored and compared with the clinician’s perception as 
described in the results of his questionnaire. Similarities 
and differences between clinician’s and patient’s percep-
tions are discussed. Based on this discussion, the treat-
ment contract is completed. During the interim evaluation 
(session III), halfway through the treatment, the goals 
and expectations are explored again with the question-
naire and the results are discussed again and adapted to 
the treatment development if necessary. At the end of the 
treatment program, a ﬁ nal evaluation (session IV) takes 
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place, based on goals and expectations as put down in the 
treatment contract. In addition, new goals and expectations 
are explored on basis of the completed questionnaire and 
ranked Q-sort cards handed out before this session. In the 
case of discontinuation of treatment before the interim or 
ﬁ nal evaluation, if possible, an exit interview with the same 
content as the ﬁ nal evaluation is carried out. A follow-up 
evaluation (session V) is carried out three months after 
treatment. In this follow-up meeting the goals and expecta-
tions are evaluated which were agreed on during the latest 
evaluation.
Three months before the start of the study clinicians of 
the experimental condition were trained in the SDMI protocol 
and in selected aspects of motivational interviewing (MI) 
techniques (Rollnick and Miller 1995). In general, MI is 
used to motivate patients for treatment in addiction health 
care. So, clinicians in the control condition also used MI. In 
the experimental condition, MI was offered in a structured 
way by protocol to explore and compare indicated treatment 
goals and ﬁ nally to reach an agreement on these goals. MI 
represented a small but essential part of SDMI. The 1-day 
training and a booster session after one month took place 
per site. A SDMI manual was used in which the sessions 
were described in detail. Furthermore, clinicians completed 
a checklist after every SDMI session to check whether they 
carried out all elements of SDMI.
Procedure
Data were collected at baseline, interim measurement after 
8 weeks of treatment, and end of treatment. At baseline, the 
ﬁ rst author introduced the study to the patients. After this 
the patient signed informed consent. Patients’ baseline data 
were collected, such as socio-demographic characteristics, 
type and severity of substance dependence problems, and 
DSM-VI diagnosis.
Patients in both SDMI and control condition received 
a nearly equal amount of 1:1 contact to reach and evaluate 
the treatment agreement. Most important difference between 
conditions was the structured and visualized way to reach a 
treatment agreement in the SDMI condition. In the control 
condition, decision-making was not as explicit and balanced 
(who takes the decision) as the SDMI. In the experimental 
condition, after baseline measurement, the trained clinician 
introduced SDMI to the patient after which they received 
SDMI. Patients allocated to control condition received the 
usual way of reaching a treatment agreement without SDMI. 
Patient’s and clinician’s perceived alliance was measured at 
interim and exit measurement.
Statistical analyses
Chi-square, or Fisher’s exact test for dichotomous data, and 
independent sample t-test were used to test for differences 
between SDMI and control condition in relation to baseline 
characteristics. Baseline analyses were performed for both 
patients and clinicians who completed at least one measure-
ment of helping alliance.
Analyses were carried out for patients, clinicians, and 
difference HAQ scores separately. HAQ subscales and total 
sum scores were computed. Difference scores (patient minus 
clinician) were computed for each patient-clinician couple 
for each measuring time-point (eg, patient minus clinician 
item score at exit). All analyses were conducted for HAQ 
total, cooperation, and helpfulness score.
The data had a nested structure with patients nested within 
clinicians. In order to account for the nested data structure 
in these analyses, Multilevel Modelling (Hox 1998, 2002) 
was used and estimation was performed using MLwiN 
(Rasbash et al 2000). Multilevel analysis was performed to 
explore whether intra-class correlation existed. Two models 
(without and with clinician variance) were tested regarding 
the patient HAQ. The difference (deviance dropped from 
1363.117 to 1361.535 = 1.582) had a Chi-squared distribution 
with 3 degrees of freedom; p  0.66; so the added clinician 
variance did not contribute signiﬁ cantly to the ﬁ t. Regarding 
the clinician HAQ, the difference (deviance dropped from 
1326.298 to 1320.268  =  6.030) had a Chi-squared distri-
bution with 3 degrees of freedom; p  0.11; so the added 
clinician variance did not contribute signiﬁ cantly to the ﬁ t. 
There was no intra-class correlation in this data. There-
fore, we were allowed to use independent sample t-tests to 
compare HAQ scores between SDMI and control condition 
for each measurement separately.
Finally, Cohen’s d = |μ
1
 – μ
2
|σ was calculated to deter-
mine the effect sizes (Cohen, 1988). Cohen deﬁ nes d’s 
of 0.2, 0.5, and 0.8 as small, medium, and large effects, 
respectively.
All statistical tests were two-sided, with a p-value of 
0.05 or less considered to indicate statistical signiﬁ cance. 
All analyses (except multilevel analyses) were performed 
using SPSS for Windows (release 14.0).
Results
Patient and clinician characteristics
Two hundred and sixty one patients were assessed for 
eligibility. Two hundred and twenty seven patients were 
approached to participate: 111 patients randomly assigned to 
SDMI and 116 patients assigned to control condition. Before 
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baseline measurement 7 patients refused to provide consent to 
participate in the study. These 7 patients were assigned to the 
control condition but were not aware of the condition. Owing 
to discontinuation of the study at one of the departments, 
8 patients did not receive the allocated treatment: 4 in SDMI 
and 4 in control condition. Two hundred and twelve patients 
were included in this study: 107 patients were assigned to 
SDMI and 105 to control condition. We found one signiﬁ cant 
difference in baseline characteristics between the two condi-
tion (n = 212). Patients’ baseline severity score Family/Social 
Relations was significantly higher among patients who 
received control intervention (t = 2.38; p  0.05).
Table 1 shows key baseline characteristics of the 
147 patients who completed at least one measurement of 
helping alliance. The remaining 65 patients left treatment 
before interim measurement or did not complete HAQ at 
interim or exit measurement. In this reduced sample, only 
patients’ baseline severity score Family/Social Relations was 
signiﬁ cantly higher among patients who received control 
intervention (t = 2.38; p  0.05). Clinicians’ baseline char-
acteristics are illustrated in Table 2. Professional qualiﬁ ca-
tions of clinicians were nurse or social worker. We found no 
signiﬁ cant differences between the two conditions regarding 
clinicians’ baseline characteristics.
Helping alliance
Table 3 illustrates patients’ and clinicians’ perceived helping 
alliance by condition at interim and exit measurement. 
Table 1 Baseline characteristics of the study population by condition (n = 147)
Characteristic SDMI Control χ2, p-value t-value, p-value
n n
Age, mean (SD), years 40.7 (10.3) 64 41.2 (11.1) 83 0.27, 0.79
Gender, % male 76.6 49 75.9 63 0.01, 1.00
Country of birth, % 1.24, 0.27
 Netherlands 92.2 59 96.4 80
 Other 7.8 5 3.6 3
Relationship, % 2.68, 0.26
 Married 12.7 8 20.7 17
 Divorced/widow 44.4 28 32.9 27
 Never married 42.9 27 46.3 38
Employment full or part-time % 62.9 39 53.8 42 1.16, 0.28
Years of education, mean (SD) 11.3 (2.7) 64 11.6 (3.1) 83 0.54, 0.59
Type of substance dependence, %
 Alcohol dependence 71.9 46 74.7 62 0.15, 0.71
 Drug dependence 43.8 28 37.3 31 0.62, 0.50
Years of substance use, mean (SD) 14.8 (8.3) 62 14.5 (10.0) 80
−0.17, 0.87
Primary substance use, % 1.03, 0.79
 Alcohol 52.4 33 59.3 48
 Cocaine/Stimulants 12.7 8 8.6 7
 Polydrug 27 17 25.9 21
 Other 7.9 5 6.2 5
EuropASI severity scores, mean (SD) 64 83
 Physical health 2.4 (2.1) 2.8 (2.1) 1.10, 0.27
 Work, education, and income 3.7 (1.7) 3.4 (2.0)
−1.00, 0.32
 Alcohol 5.2 (2.6) 5.3 (2.5) 0.34, 0.73
 Drugs 3.4 (3.3) 2.9 (3.2)
−0.92, 0.36
 Legal 1.5 (1.9) 1.4 (1.8)
−0.12, 0.91
 Family/social relations 3.8 (1.5) 4.4 (1.5) 2.46, 0.02*
 Psych./emotional problems 5.8 (2.0) 5.8 (2.0) 0.03, 0.97
 Gambling 0.5 (1.5) 0.4 (1.2) 0.20, 0.85
*p  0.05.
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Unfortunately, perceived helping alliance was not measured 
when patients left treatment before interim measurement 
(n = 78). No differences were found between conditions 
regarding patient’s perceived alliance. Patients’ scores on 
the HAQ were particularly high, even at interim measure-
ment (mean scores between 44 and 48 out of a maximum 
total score of 55).
A significant difference between SDMI and control 
condition was measured on the HAQ completed by clini-
cians. Helpfulness (t = 2.44, p  0.05 and t = 2.82, p  0.01 
respectively at interim and exit measurement) and total 
score (t = 2.01, p  0.05 and t = 3.01, p  0.01 respectively 
at interim and exit measurement) were signiﬁ cantly higher 
when clinicians carried out SDMI. Table 3 also shows 
effect sizes calculated by Cohen d. Medium effects with 
ranges d 0.41 to 0.62 were found for these signiﬁ cant variables. 
We also computed a difference score within each patient-
clinician couple for each assessment time separately (see 
Table 4). We found a signiﬁ cant difference between conditions 
concerning HAQ total score at exit measurement (t = −2.44, 
p  0.05). The difference between patient and clinician was 
signiﬁ cantly smaller when SDMI was carried out.
Discussion
The purpose of this study was to evaluate the inﬂ uence 
of a SDMI on patients’ and clinicians’ perceptions of 
Table 2 Baseline characteristics of the clinicians by condition (n = 34)
Characteristic SDMI Control χ2, p-value t-value, p-value
n n
Age, mean (SD), years 35.6 (12.4) 16 34.1 (12.0) 18 0.36, 0.72
Gender, % male 31.3 5 44.4 8 0.62, 0.50
Years of working experience, mean (SD) 13.1 (11.6) 16 12.6 (11.5) 18 0.13, 0.90
Table 3 Patient’s and clinician’s perceived alliance (HAQ) at interim and exit measurement
HAQ
Mean (SD)
n SDMI n Control n Total t-value P-value ES
d
Patient
Interim (T3)
 Cooperation 54 20.1 (2.5) 66 19.7 (3.7) 120 19.9 (3.1) 0.73 0.46 0.13
 Helpfulness 55 20.1 (2.6) 66 20.2 (2.8) 121 20.2 (2.7)
−0.10 0.92 0.04
 Total 54 44.7 (4.1) 66 44.1 (6.3) 120 44.4 (5.4) 0.61 0.55 0.11
Patient
Exit (T4)
 Cooperation 50 20.5 (2.7) 53 21.2 (3.2) 103 20.8 (3.0)
−1.13 0.26 0.24
 Helpfulness 50 21.7 (2.3) 54 21.8 (3.0) 104 21.8 (2.7)
−0.14 0.89 0.04
 Total 50 46.6 (4.7) 53 47.5 (6.3) 103 47.1 (5.6)
−0.82 0.42 0.16
Clinician
Interim (T3)
 Cooperation 52 18.9 (2.3) 71 18.6 (2.3) 123 18.7 (2.3) 0.63 0.53 0.13
 Helpfulness 53 19.0 (2.4) 73 17.8 (3.2) 126 18.3 (3.0) 2.44 0.02* 0.42
 Total 52 42.2 (4.4) 71 40.2 (5.4) 123 41.0 (5.1) 2.01 0.05* 0.41
Clinician
Exit (T4)
 Cooperation 49 18.9 (2.3) 47 18.3 (2.5) 96 18.6 (2.4) 1.10 0.27 0.25
 Helpfulness 49 19.5 (2.6) 47 17.6 (4.1) 96 18.6 (3.5) 2.82 0.01** 0.55
 Total 48 42.6 (4.2) 47 39.4 (6.0) 95 41.0 (5.4) 3.01 0.01** 0.62
*p  0.05.
**p  0.01.
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therapeutic alliance. Results of the present study showed 
that SDMI resulted in clinicians perceiving the alliance more 
favorable, and also in greater congruence between clinicians’ 
perceptions and those of the patients. Effect sizes showed 
a medium effect for these signiﬁ cant ﬁ ndings. There was 
no signiﬁ cant difference between conditions with regard to 
patients’ perceptions of the alliance. It has to be taken into 
consideration here that patients in the experimental condition 
received SDMI on top of an intensive inpatient treatment that 
was also given to the patients in the control condition.
There are several limitations to the present study that 
should be noted. Patients and clinicians were not blinded to 
the intervention and this might have inﬂ uenced the results. 
SDMI might have inﬂ uenced the way of decision-making 
to reach a treatment agreement within the control condition. 
Furthermore, therapeutic alliance might have been overesti-
mated by clinicians in the SDMI condition. Results showed 
that clinicians who carried out SDMI only scored higher 
on the Helpfulness scale and not on the Cooperation scale. 
Clinicians should have scored higher on the Cooperation 
scale if they overestimated the therapeutic alliance. As noted 
before, HAQ scores were all very high. This ceiling effect is 
likely to have made it more difﬁ cult to demonstrate further 
improvements in HAQ scores with SDMI. Patient-clinician 
alliance was measured by a self-report questionnaire and 
it might be possible that social desirability has inﬂ uenced 
the scores. Another limitation is that most patients who 
left treatment prematurely did not complete the HAQ. It is 
important to notice that there was no difference between 
conditions with regard to treatment drop-out. Future research 
should concern patient’s perception of alliance before they 
drop-out of treatment. Furthermore, it has to be mentioned 
that patients’ baseline severity score on Family/Social 
Relations was higher among patients who received control 
intervention. It is not very probable that the higher severity 
score on Family/Social Relations in the control condition 
led to a lower score of perceived alliance, although this 
possibility cannot be excluded. A major strength of this trial 
is its longitudinal prospective design, with multiple measure-
ment of therapeutic alliance during and after treatment. Other 
strengths of this study include its multi-centre nature and few 
barriers to patient recruitment.
Results of this study indicate that SDMI is an effec-
tive method to increase clinicians’ perceptions of alliance. 
However, patients’ perceptions of the therapeutic alliance 
were not enhanced by SDMI. This is in contrast with results 
from a previous study which found that SDM had a greater 
effect on patients’ perceptions than on those of the clini-
cians (Bieber et al 2008). In this study, ﬁ bromyalgia patients 
received the information tool during the ﬁ rst session before 
they discussed their treatment plan with their clinician. In 
our study, substance-dependent patients discussed and evalu-
ated their treatment plan during three SDM sessions. Before 
these sessions patients and clinicians completed the Goals 
of Treatment questionnaire to indicate treatment goals and 
arranged these goals in order of importance and priority by 
using Q-sort cards.
A reason for not ﬁ nding differences between patients in 
SDMI and control condition might be that the HAQ was not 
sensitive enough to measure greater differences and greater 
changes over time in the perception of therapeutic alliance 
due to the ceiling effect. In comparison with patients, clini-
cians are able to compare the alliance with a speciﬁ c patient 
to the alliance with other patients. Perhaps the therapeutic 
alliance is more a moderating factor of treatment outcome 
(McGuire et al 2001). More research is therefore needed to 
explore the effect of SDMI on therapeutic alliance in relation 
with treatment outcome.
Table 4 Difference score (patient minus clinician) HAQ at interim and exit measurement
HAQ
Mean (SD)
n SDMI n Control n Total t-value P-value
Interim (T3)
 Cooperation 49 1.3 (2.8) 63 1.1 (3.8) 112 1.2 (3.4) 0.31 0.75
 Helpfulness 50 1.4 (2.9) 65 2.5 (4.4) 115 2.0 (3.8)
−1.66 0.10
 Total 49 2.9 (5.3) 63 3.9 (8.1) 112 3.5 (7.0)
−0.79 0.43
Exit (T4)
 Cooperation 47 1.3 (2.9) 41 2.5 (3.4) 88 1.9 (3.2)
−1.70 0.09
 Helpfulness 48 2.1 (2.9) 41 3.6 (4.2) 89 2.8 (3.7)
−1.88 0.06
 Total 47 3.7 (5.4) 41 7.0 (7.3) 88 5.3 (6.5)
−2.44 0.02*
*p  0.05.
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Clinicians who performed SDMI scored especially 
higher on the Helpfulness scale. The perception of these 
clinicians appeared to be more positive regarding their 
patient’s capacities in improving their situation. These 
clinicians also perceived positive effectiveness of the 
treatment. This is an important ﬁ nding because patients 
diagnosed with substance related disorders are assumed 
to be more difﬁ cult to treat (Najavits et al 2000). SDMI 
seems to help clinicians to deal with these patients by 
increasing their perceptions of their own helpfulness. 
SDMI leads to greater congruence between clinicians’ 
and patients’ perceptions of therapeutic alliance. This is 
not only caused by clinicians’ scores but also by patients’ 
scores regarding the perceived alliance. This congruence 
between the patient and the clinician is favorable for the 
therapeutic relationship.
Therapeutic alliance is an important topic in addiction 
treatment. The present study has shown that a specific 
intervention to enhance shared decision-making leads to a 
better clinician’s perceived alliance and more involvement. 
This improved alliance is likely to be a helpful prerequisite 
for good treatment outcome, but further research is needed 
to demonstrate whether SDMI by improving therapeutic 
alliance is a signiﬁ cant predictor for improved treatment 
outcome.
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